Using New Blood RNA Tests to Detect and Classify Long COVID

What this Trial Is About

Researchers are studying Long COVID by analyzing specific blood RNA patterns to develop an algorithm that can identify and classify this condition among different patient groups. The goal is to distinguish Long COVID from normal health and other medical conditions that have similar symptoms. This interventional study aims to create a reliable diagnostic test for detecting the presence and severity of Long COVID. Participants provide two blood samples about 28 days apart and complete surveys about their ethnicity, medical history, and symptoms. Based on their responses, they are assigned to one of fourteen groups reflecting various types of Long COVID or control groups without infection or with other prior conditions. Blood samples are sent to the study sponsor, where an AI process will analyze RNA sequences to validate the Long COVID type and severity. During the study, participants complete surveys and undergo two blood draws. Researchers will measure RNA sequences to develop algorithms that classify Long COVID and its subtypes within 30 days. The study includes participants aged 18 and older, including healthy volunteers, and monitors safety through single masking. The full participation timeline includes initial screening and sample collection with follow-up assessments approximately one month apart.

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19